Northwestern University Feinberg School of Medicine, Department of Dermatology
Chicago, Illinois, 60611, United States
NCT Number: NCT03066843
This is a randomized clinical trial evaluating blue light 5-aminolevulinic acid (ALA) photodynamic therapy with different incubation times for the treatment of actinic keratosis.
Subjects who are interested in participating, currently living in the Chicago metropolitan area, and meet inclusion and exclusion criteria will be enrolled in the study. Subjects will be randomized to either 1) zero time ALA incubation or 2) 1 hour ALA incubation. Demographic and health data will be collected prior to treatment initiation. Three visits will be conducted: screening, treatment, and follow up visit at 8 weeks.
This study is a pilot study designed to determine feasibility of this procedure.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Chicago, Illinois, 60611, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
ALA (5-aminolevulinic acid) will be applied to subjects' skin for either zero time incubation or one hour incubation
Other names: Levulon kerastick
Subjects will be exposed to blue light
Other names: BLU-U® Blue Light Photodynamic Therapy Illuminator
Time frame: Baseline and 8 Weeks
The number of AK lesions will be counted by a live, blinded assessor at baseline and at Week 8 follow-up visit.
Northwestern University
Other
A Randomized Controlled Trial Evaluating 5-aminolevulinic Acid Photodynamic Therapy With Different Incubation Times for the Treatment of Actinic Keratosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05662202
Actinic Keratoses, Keratosis
Phoenix, Arizona, United States
View Trial DetailsNCT07428941
Actinic Keratoses, Bacterial Infections
Bilbao, Basque Country, Spain
View Trial DetailsNCT05923060
Actinic Keratoses, Keratosis
Cleveland, Ohio, United States
View Trial DetailsNCT07053852
Actinic Keratoses, Keratosis
Victor, New York, United States
View Trial Details